Effect on LDL-cholesterol of a large dose of a dietary supplement with plant extracts in subjects with untreated moderate hypercholesterolaemia: A randomised, double-blind, placebo-controlled study

European Journal of Nutrition

Volumn 52, Issue 8, 2013, Pages 1843-1852

  Barrat, Emmanuel ^a   Zaïr, Yassine ^b   Sirvent, Pascal ^a   Chauveau, Patrice ^c   Maudet, Corinne ^c   Housez, Béatrice ^c   Derbord, Elodie ^a   Lescuyer, Jean François ^a   Bard, Jean Marie ^a   Cazaubiel, Murielle ^c   Peltier, Sébastien L ^a  

^a UNIVERSITÉ DE NANTES   (France)

^b NANTES UNIVERSITY HOSPITAL   (France)

^c Biofortis Mérieux Nutrisciences Company   (France)

Author keywords

Artichoke leaf extract; Muscle breakdown; Policosanols; Red yeast rice; Withdrawal

Indexed keywords

ARTICHOKE LEAF EXTRACT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PLANT EXTRACT; POLICOSANOL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; XUEZHIKANG;

ADULT; ANIMAL CELL; ARTICHOKE; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DIET SUPPLEMENTATION; DOSAGE SCHEDULE COMPARISON; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; KIDNEY FUNCTION; LIPID BLOOD LEVEL; LIVER; MALE; MITOCHONDRIAL RESPIRATION; NONHUMAN; PATIENT SAFETY; PLANT LEAF; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; SKELETAL MUSCLE; UNSPECIFIED SIDE EFFECT;

CYNARA SCOLYMUS; RATTUS;

ADOLESCENT; ADULT; AGED; ANIMALS; ANTICHOLESTEREMIC AGENTS; BIOLOGICAL MARKERS; BIOLOGICAL PRODUCTS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CYNARA SCOLYMUS; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; ENDPOINT DETERMINATION; FATTY ALCOHOLS; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; LIFE STYLE; MALE; MIDDLE AGED; MITOCHONDRIA; MUSCLE, SKELETAL; PLANT EXTRACTS; PLANT LEAVES; RATS; RATS, WISTAR; RECOMMENDED DIETARY ALLOWANCES; TRIGLYCERIDES; YOUNG ADULT;

EID: 84890565328     PISSN: 14366207     EISSN: 14366215     Source Type: Journal    
DOI: 10.1007/s00394-012-0486-2     Document Type: Article

References (29)

1. Reiner Z, Catapano AL, De Backer G, et al. (2011) ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 32(14):1769-1818
2. Smith SC Jr, Benjamin EJ, Bonow RO, et al. (2011) AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation 124(22):2458-2473
3. Mancini GB, Baker S, Bergeron J, et al. (2011) Diagnosis, prevention, and management of statin adverse effects and intolerance: proceedings of a Canadian Working Group Consensus Conference. Can J Cardiol 27(5):635-662
4. Liu J, Zhang J, Shi Y, et al. (2006) Chinese red yeast rice (Monascus purpureus) for primary hyperlipidemia: a meta-analysis of randomized controlled trials. Chin Med 1:4
5. Lu Z, Kou W, Du B, et al. (2008) Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction. Am J Cardiol 101(12):1689-1693
6. Klimek M, Wang S, Ogunkanmi A (2009) Safety and efficacy of red yeast rice (Monascus purpureus) as an alternative therapy for hyperlipidemia. Pharm Ther 34(6):313-327
7. Wider B, Pittler MH, Thompson-Coon J, et al. (2009) Artichoke leaf extract for treating hypercholesterolaemia. Cochrane Database Syst Rev (4):CD003335
8. Gouni-Berthold I, Berthold HK (2002) Policosanol: clinical pharmacology and therapeutic significance of a new lipid-lowering agent. Am Heart J 143(2):356-365
9. Berthold HK, Unverdorben S, Degenhardt R, et al. (2006) Effect of policosanol on lipid levels among patients with hypercholesterolemia or combined hyperlipidemia: a randomized controlled trial. JAMA 295(19):2262-2269
10. Ogier N, Amiot MJ, George S, et al. (2012) LDL-cholesterol-lowering effect of a dietary supplement with plant extracts in subjects with moderate hypercholesterolemia. Eur J Nutr [Epub ahead of print]
11. Sirvent P, Mercier J, Lacampagne A (2008) New insights into mechanisms of statin-associated myotoxicity. Curr Opin Pharmacol 8(3):333-338
12. Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18(6):499-502
13. Sirvent P, Bordenave S, Vermaelen M, et al. (2005) Simvastatin induces impairment in skeletal muscle while heart is protected. Biochem Biophys Res Commun 338(3):1426-1434
14. Saks VA, Veksler VI, Kuznetsov AV, et al. (1998) Permeabilized cell and skinned fiber techniques in studies of mitochondrial function in vivo. Mol Cell Biochem 184(1-2):81-100
15. Jiang FY, Sun LP, Yang J (2011) Effects of xuezhikang at different doses on patients suffering from acute coronary syndrome after percutaneous coronary intervention. Zhongguo Zhong Xi Yi Jie He Za Zhi 31(12):1607-1610 (In Chinese)
16. Pons P, Rodriguez M, Robaina C, et al. (1994) Effects of successive dose increases of policosanol on the lipid profile of patients with type II hypercholesterolaemia and tolerability to treatment. Int J Clin Pharmacol Res 14(1):27-33
17. Crouse JR 3rd, Lukacsko P, Niecestro R, et al. (2002) Dose response, safety, and efficacy of an extended-release formulation of lovastatin in adults with hypercholesterolemia. Am J Cardiol 89(2):226-229
18. Hunninghake DB, Knopp RH, Schonfeld G, et al. (1990) Efficacy and safety of pravastatin in patients with primary hypercholesterolemia. I. A dose-response study. Atherosclerosis 85(1):81-89
19. Jacotot B, Banga JD, Pfister P, et al. (1994) Efficacy of a low dose-range of fluvastatin (XU 62-320) in the treatment of primary hypercholesterolaemia. A dose-response study in 431 patients. The French-Dutch Fluvastatin Study Group. Br J Clin Pharmacol 38(3):257-263
20. Saito Y, Goto Y, Dane A, et al. (2003) Randomized dose-response study of rosuvastatin in Japanese patients with hypercholesterolemia. J Atheroscler Thromb 10(6):329-336
21. Heber D, Yip I, Ashley JM, et al. (1999) Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement. Am J Clin Nutr 69(2):231-236
22. Englisch W, Beckers C, Unkauf M, et al. (2000) Efficacy of artichoke dry extract in patients with hyperlipoproteinemia. Arzneimittelforschung 50(3):260-265
23. Castano G, Fernandez L, Mas R, et al. (2002) Comparison of the efficacy, safety and tolerability of original policosanol versus other mixtures of higher aliphatic primary alcohols in patients with type II hypercholesterolemia. Int J Clin Pharmacol Res 22(2):55-66
24. Chen H, Ren JY, Xing Y, et al. (2009) Short-term withdrawal of simvastatin induces endothelial dysfunction in patients with coronary artery disease: a dose-response effect dependent on endothelial nitric oxide synthase. Int J Cardiol 131(3):313-320
25. Tomaszewski M, Stepien KM, Tomaszewska J, et al. (2011) Statin-induced myopathies. Pharmacol Rep 63(4):859-866
26. Kaufmann P, Torok M, Zahno A, et al. (2006) Toxicity of statins on rat skeletal muscle mitochondria. Cell Mol Life Sci 63(19-20):2415-2425
27. Kwak HB, Thalacker-Mercer A, Anderson EJ, et al. (2012) Simvastatin impairs ADP-stimulated respiration and increases mitochondrial oxidative stress in primary human skeletal myotubes. Free Radical Biol Med 52(1):198-207
28. Sirvent P, Fabre O, Bordenave S, et al. (2012) Muscle mitochondrial metabolism and calcium signaling impairment in patients treated with statins. Toxicol Appl Pharmacol 259(2):263-268
29. Bouitbir J, Charles AL, Rasseneur L, et al. (2011) Atorvastatin treatment reduces exercise capacities in rats: involvement of mitochondrial impairments and oxidative stress. J Appl Physiol 111(5):1477-1483